2002, Number 6
<< Back Next >>
Gac Med Mex 2002; 138 (6)
A U.S. National Institutes of Health investigation suspended due to risk of breast cancer with use of hormone replacement in menopause.
Zárate-Treviño A
Language: Spanish
References: 6
Page: 595-596
PDF size: 18.11 Kb.
Text Extraction
No abstract
REFERENCES
Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-741.
Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II) JAMA 2002;288:49-57.
Hulley S, Furberg C, Barret-Connor E. Noncardiovascular disease outcomes during 6.8 years or hormone replacement therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2001;288:58-66.
Zárate A, Hernández M. Terapia de reemplazo hormonal en mujeres menopáusicas tratadas por cáncer mamario. Rev Med IMSS 2002;40:369-371.
Ross RK, Paganini-Hill A, Wan P, Pike M. Effect of hormone replacement therapy on breast cancer: estrogen versus- estrogen plus progestin. J Natl Cancer Inst. 2000;92:328-332.
Full text